Human adipose-derived cells have been shown to be a suitable cell source to generate bone tissue in vivo either by direct intramembranous ossification or by endochondral ossification, through their capacity to differentiate into osteoblasts or hypertrophic chondrocytes, upon adequate triggering. Therefore, they are a cell source of choice for the therapeutic regeneration of bone and cartilage defects in patients. However, a lot remains to be discovered about the biology, functionality, and heterogeneity of those cells. This knowledge is key to stimulate their bone and cartilage formation capacity and to design strategies for skeletal regeneration.
The aim of the current Research Topic is to cover recent and novel research about the use of adipose-derived cells for the regeneration of cartilage, bone, or osteochondral defects. Studies investigating the biology of adipose-derived cells and their commitment into skeletal lineages, including vascular cells, are encouraged. The following types of manuscripts are welcome: Original Research, Review, and Case Reports.
Areas to be covered in this Research Topic include, but are not limited to:
• Culture and selection of more potent adipose-derived cells
• In vitro studies of the biology and osteogenic performance of adipose-derived cells
• Use of uncultured, stromal vascular fraction (SVF) cells for skeletal regeneration
• Use of bioreactor systems and other enabling technologies (printing, cell aggregation, cell isolation, etc.)
• Preclinical and clinical studies in skeletal regeneration
• Intramembranous or endochondral ossification
Dr. Arnaud Scherberich is a shareholder of Cellec Biotek AG and Dr. Daniele Noel is a co-founder of the company MedXcell Science. All other Topic Editors declare no conflicts of interest in regarding to this Research Topic.
Human adipose-derived cells have been shown to be a suitable cell source to generate bone tissue in vivo either by direct intramembranous ossification or by endochondral ossification, through their capacity to differentiate into osteoblasts or hypertrophic chondrocytes, upon adequate triggering. Therefore, they are a cell source of choice for the therapeutic regeneration of bone and cartilage defects in patients. However, a lot remains to be discovered about the biology, functionality, and heterogeneity of those cells. This knowledge is key to stimulate their bone and cartilage formation capacity and to design strategies for skeletal regeneration.
The aim of the current Research Topic is to cover recent and novel research about the use of adipose-derived cells for the regeneration of cartilage, bone, or osteochondral defects. Studies investigating the biology of adipose-derived cells and their commitment into skeletal lineages, including vascular cells, are encouraged. The following types of manuscripts are welcome: Original Research, Review, and Case Reports.
Areas to be covered in this Research Topic include, but are not limited to:
• Culture and selection of more potent adipose-derived cells
• In vitro studies of the biology and osteogenic performance of adipose-derived cells
• Use of uncultured, stromal vascular fraction (SVF) cells for skeletal regeneration
• Use of bioreactor systems and other enabling technologies (printing, cell aggregation, cell isolation, etc.)
• Preclinical and clinical studies in skeletal regeneration
• Intramembranous or endochondral ossification
Dr. Arnaud Scherberich is a shareholder of Cellec Biotek AG and Dr. Daniele Noel is a co-founder of the company MedXcell Science. All other Topic Editors declare no conflicts of interest in regarding to this Research Topic.
